Clinical Research Directory

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has one of the following diagnoses: * Recurrent, pathologically documented epithelial OC, primary peritoneal cancer, or fallopian tube cancer that is either (1) platinum resistant or (2) platinum sensitive, with progression during prior treatment with poly-adenosine diphosphate (ADP) ribose polymerase inhibitor (PARPi) * Histologically confirmed well, moderately, or poorly differentiated (ie, Grade 1 to Grade 3) serous or endometrioid EC that has progressed after at least 1 line of platinum-based therapy in any setting * Has received all protocol-required and available standard of care (SOC) therapies, unless ineligible for or intolerant to the therapies * Has provided archival tumor tissue or a recently obtained biopsy before treatment start * If living with human immunodeficiency virus (HIV), has well-controlled HIV on antiretroviral therapy (ART) * If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral - therapy for at least 4 weeks * If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load * Has adequate organ function Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a diagnosis of any 1 of the following: Primary platinum-refractory OC; neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of pure sarcomas; carcinosarcoma; EC that is amenable to curative-intent surgery or curative-intent radiotherapy; or EC that requires recurrent drainage of effusions * Has a history of serious cardiovascular and cerebrovascular diseases * Has a history or presence of clinically relevant central nervous system (CNS) diseases * Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before start of study intervention * Has received prior radiotherapy within 2 weeks of start of study intervention * Has known additional malignancy that is progressing or has required active treatment within the past 3 years * Has known active CNS metastases and/or carcinomatous meningitis * Has active autoimmune disease that has required systemic treatment in the past 2 years * Is living with HIV and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has a history of stem cell/solid organ transplant * Has not adequately recovered from major surgery or has ongoing surgical complications